D
Dyne Therapeutics
Dyne Therapeutics is a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases
About Dyne Therapeutics
Dyne Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of therapies for serious muscle diseases. The company serves a niche market of patients living with rare muscle diseases, their families, and caregivers. Dyne's business model is centered around its proprietary FORCE™ platform, a technology that enhances the delivery of modern oligonucleotide therapeutics to muscle tissue. This technology is used to develop a broad portfolio of therapies aimed at improving the lives of those affected by muscle diseases.
Read full description
Dyne's primary revenue stream comes from the development and commercialization of these therapies. The company is currently in the clinical trial phase for several of its therapies, as indicated by its recent financial results and updates on the ACHIEVE and DELIVER trials. As a biotech startup, Dyne is likely to be in the investment phase, with revenues expected to grow significantly once its therapies receive regulatory approval and are commercialized.
The company's commitment to people living with serious muscle diseases is a key part of its brand identity. This commitment is reflected in its supportive work environment, which it promotes as a strength that sets it apart from other companies in the sector.
At a glance
- Founded
- 2017
- Headquarters
- Waltham, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A9 investors entered at this stage
Atlas Venture
Cure Duchenne
Forbion Capital Partners
Franklin Templeton Investments
Citadel
MPM BioImpact
Vida Ventures
Logos Capital
Wellington Management
Series B and later1 investor entered at this stage
Hercules Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
48 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dyne Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dyne Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.